Increased EZH2 expression is associated with proliferation and progression of cervical cancer and indicates a poor prognosis

International Journal of Gynecological Pathology

Volumn 33, Issue 3, 2014, Pages 218-224

  Liu, Yueyang ^a   Liu, Ting ^a   Bao, Xiangxiang ^a   He, Miaolong ^a   Li, Ling ^a   Yang, Xingsheng ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Cervical cancer; EZH2; Immunohistochemistry.; Prognosis; Proliferation

Indexed keywords

KI 67 ANTIGEN; TRANSCRIPTION FACTOR EZH2; EZH2 PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR VOLUME; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VERY ELDERLY; YOUNG ADULT; CELL PROLIFERATION; DISEASE COURSE; GENETICS; KAPLAN MEIER METHOD; METABOLISM; PATHOLOGY; PRECANCER; PROGNOSIS; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; CERVICAL INTRAEPITHELIAL NEOPLASIA; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; POLYCOMB REPRESSIVE COMPLEX 2; PRECANCEROUS CONDITIONS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84898597753     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31829c6574     Document Type: Article

References (23)

1. Arbyn M, Castellsague X, de Sanjose S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-86.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3. Holland D, Hoppe-Seyler K, Schuller B, et al. Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein. Cancer Res 2008;68:9964-72.
4. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell 2004;15:57-7.
5. Montgomery ND, Yee D, Chen A, et al. The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation. Curr Biol 2005;15:942-47.
6. Hussein YR, Sood AK, Bandyopadhyay S, et al. Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Human Pathol 2012;43: 1638-44.
7. Xiao Y. Enhancer of zeste homolog 2: a potential target for tumor therapy. Int J Biochem Cell Biol 2011;43:474-77.
8. Simon JA, Tamkun JW. Programming off and on states in chromatin: mechanisms of Polycomb and trithorax group complexes. Curr Opin Genet Dev 2002;12:210-18.
9. Wang H, Albadine R, Magheli A, et al. Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urol Oncol Semin Orig Investig 2011;30:428-33.
10. Liu D-C, Yang Z-L. Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma. Pathol Res Pract 2011;207:472-78.
11. Lee H, Yoon SO, Jeong WY, et al. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer. Hum Pathol 2012;43:1704-10.
12. Choi JH, Song YS, Yoon JS, et al. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer. APMIS 2010;118:196-202.
13. Lv Y, Yuan C, Xiao X, et al. The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma. Oncol Rep 2012;28:147-54.
14. Ren G, Baritaki S, Marathe H, et al. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Res 2012;72:3091-104.
15. Mallen-St. Clair J, Soydaner-Azeloglu R, Lee KE, et al. EZH2 couples pancreatic regeneration to neoplastic progression. Genes Dev 2012;26:439-44.
16. Rao ZY, Cai MY, Yang GF, et al. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 2010;31:1576-83.
17. Guo J, Cai J, Yu L, et al. EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo. Cancer Sci 2011;102:530-39.
18. Fang J, Zhang M, Li Q. Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and invasion in cervical cancer. Am J Med Sci 2011;342: 198-4.
19. Bracken AP, Pasini D, Capra M, et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22:5323-35.
20. Blagosklonny MV, Yang X, Karuturi RKM, et al. CDKN1C (p57KIP2) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS ONE 2009;4:e5011.
21. Wagener N, Macher-Goeppinger S, Pritsch M, et al. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 2010; 10:524-533.
22. Shin YJ, Kim JH. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. PLoS ONE 2012;7:e30393.
23. Fujii S, Ito K, Ito Y, et al. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 2008;283:17324-32.